Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more) Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Acasti Pharma Inc ACST

Healthcare
Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the... see more

NDAQ:ACST - Post Discussion

Acasti Pharma Inc > Oppenheimer still rates this a Buy
View:
Post by Canadian_101 on Jun 30, 2020 8:11am

Oppenheimer still rates this a Buy

Well looks like they saw or heard something I did not or simply are hoping the next set of trial results are going to be a lot better!!!

Will continue to hold a core position  till T2 results are released, ( there is some hope for good results).....  but will also be trading as opportunities arise....




6/30/2020 Oppenheimer Reiterated Rating Buy $7.00 N/A
Comment by Rosmorduc on Jun 30, 2020 8:15am
Well, Jan stated clearly that based on the data and deep intel they have, Trilogy 2 will be sufficient to push CAPRE to approval. As I said yesterday, see this as a gift and load up more here. CAPRE is a blockbuster drug. Management....ehhhhh. Nut CAPRE is what counts here. 
Comment by lscfa on Jun 30, 2020 9:51am
$7.00 US.  target..... Oppenheimer Thinks Acasti Pharma’s Stock is Going to Recover Ryan Adist- June 30, 2020, 7:17 AM EDT  SHARE ON:     In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Acasti Pharma (ACST), with a price target of $7.00. The company’s shares closed last Monday at $0 ...more  
Acasti Pharma Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities